Video Experimental Relacionado
Updated: Sep 10, 2025
08:28
Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods
Published on: March 10, 2020
7.0K
Uso de estatinas durante el embarazo y riesgo de malformaciones congénitas: un estudio nacional noruego
Jacob J Christensen1, Kirsten B Holven1,2, Martin P Bogsrud3
1Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, Oslo 0317, Norway.
European heart journal
|August 21, 2025
Resumen
Este estudio no encontró una relación significativa entre la exposición a estatinas o agentes modificadores de los lípidos (LMA) durante el embarazo y las malformaciones congénitas. Los hallazgos sugieren que estos medicamentos son probablemente seguros para el desarrollo fetal.
Área de la Ciencia:
- Salud Reproductiva
- Farmacología cardiovascular
- Teratología
Sus antecedentes:
- Las estatinas y los LMA tradicionalmente contraindicados en el embarazo debido a preocupaciones de seguridad.
- Datos limitados sobre los riesgos de exposición intrauterina a las estatinas y a las LMA.
- Necesidad de aclarar las asociaciones entre el uso materno de LMA y los resultados fetales.
Objetivo del estudio:
- Examinar las asociaciones entre la exposición a estatinas/LMA en el primer trimestre y las malformaciones congénitas.
- Actualizar un metaanálisis de 2022 con los datos actuales del estudio.
- Evaluar los riesgos de la exposición a estatinas y LMA durante el embarazo humano.
Principales métodos:
- Se utilizaron datos del registro nacional noruego (2005-2018) para mujeres embarazadas.
- Utilizó regresión logística de efectos mixtos para evaluar las asociaciones.
- Se han realizado metanálisis utilizando modelos de variación inversa y efectos aleatorios.
Principales resultados:
- No hay asociación significativa entre la exposición a estatinas y cualquier malformación mayor o menor.
- No hay aumento del riesgo de malformaciones cardíacas con la exposición a LMA.
- El metanálisis actualizado no mostró un aumento en el riesgo de malformaciones cardíacas o mayores (OR 1,06 y 1,24).
Conclusiones:
- Este amplio estudio y el metanálisis no encontraron una asociación significativa entre la exposición a estatinas/ LMA en el primer trimestre y las malformaciones congénitas.
- Los hallazgos no apoyan un vínculo fuerte o independiente entre el uso de estatinas maternas y los defectos de nacimiento.
- Si bien las asociaciones débiles no pueden descartarse por completo, la evidencia actual sugiere seguridad.
Videos de Conceptos Relacionados
01:07Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
01:19Mitral Valve Prolapse III: Nursing Management
36
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
36
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
598
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
598
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
430
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
430
01:26Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21